National Health Insurance Administration: In addition to the centralized procurement agreement, medical institutions can use other non-selected products, including innovative drugs, to avoid a "one-size-fits-all" approach.

This morning, Shi Zihai, deputy director of the National Medical Security Administration, stated at a regular policy briefing of the State Council that it is necessary to strengthen the coordinated linkage between medical treatment, medical insurance, and pharmaceuticals, enhance departmental collaboration, and generate comprehensive effects. For medical institutions, the focus is on guiding them to prioritize the use of selected products according to regulations and reporting requirements. Outside of centralized procurement agreements, medical institutions can use other non-selected products, including original drugs, to avoid a one-size-fits-all approach in clinical selection and better meet the diverse medication needs of patients. For selected enterprises, the main responsibility is to solidify the quality and supply guarantee of selected enterprises, always adhere to a "zero tolerance" policy towards drug quality and supply issues, strictly deal with enterprises that fail to supply timely or affect clinical use, and ensure stable and reliable supply of clinical drugs.